The expression level and activity of SP1 are often abnormally elevated in lung cancer tissues, and its high expression is significantly associated with a poor prognosis (Beishline and Azizkhan-Clifford, 2015), To make it a potential therapeutic target, inhibiting SP1 or its downstream pathways has demonstrated anti-tumor effects in preclinical studies. This evidence concerns the gene SP1 and lung cancer.